Full-Time

Pharmacist

Posted on 5/9/2026

Mass General Brigham

Mass General Brigham

1-10 employees

Early-stage life science venture investor

Compensation Overview

$91.2k - $132.6k/yr

Peabody, MA, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • To perform this job successfully, an individual must be able to perform each duty satisfactorily and be able to proficiently demonstrate computer applications.
  • Requires attention to detail and concentration.
  • Good analytical skills are a must.
  • Ability to manage a large number of tasks simultaneously and to anticipate future needs.
  • Ability to communicate with a wide variety of professionals and non-professionals.
  • New grads require 2 years experience in a clinical setting as a pharmacy intern.
  • Minimum of 2 years experience working in a clinical environment preferred.
  • Graduate from an accredited college of pharmacy is required.
  • Current licensure as a Pharmacist by the State of Massachusetts is required.
Responsibilities
  • The procurement, distribution, and control of all pharmaceuticals used within the North Shore Medical Center.
  • The evaluation and dissemination of comprehensive information about drugs and their use to the institution’s staff and patients.
  • The monitoring, evaluation, and assurance of the quality of drug use.
  • These functions are carried out in cooperation with other institutional departments and programs.
  • Pharmacists oversee the activities of technicians and pharmacy students, and participate in maintaining the department’s functions.

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.7B

Headquarters

Cambridge, Massachusetts

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • 20 exits since inception including eight IPOs and twelve acquisitions demonstrate proven value creation.
  • Strategic focus on digital health and AI positions firm for high-growth healthcare innovation trends.
  • Integrated academic-clinical ecosystem provides technical validation and talent pipeline advantages.

What critics are saying

  • Escalating nurse strikes at Mass General Brigham disrupt operations and damage institutional reputation.
  • Portfolio company failures like Instride erode LP confidence and future fundraising capacity.
  • Competing VCs from non-MGB institutions capture superior deal flow, limiting proprietary advantage.

What makes Mass General Brigham unique

  • Proprietary deal flow from Mass General Brigham's research community and Harvard Medical School faculty.
  • Dedicated AI and Digital Innovation Fund targeting venture-stage healthcare companies since 2020.
  • Active company building support through Amplify program beyond capital provision.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Mass General Brigham who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Hybrid Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Family Planning Benefits

Fertility Treatment Support

Professional Development Budget

Conference Attendance Budget

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Stock Options

Company Equity

401(k) Company Match

Parental Leave

Adoption Assistance

Childcare Support

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Company News

PR Newswire
Mar 19th, 2026
MGB Home Care clinicians to picket Mass General over stalled contract talks after year of bargaining

Approximately 450 clinicians at Mass General Brigham Home Care, represented by the Massachusetts Nurses Association, will hold an informational picket on 24 March outside Massachusetts General Hospital. The clinicians are seeking their first union contract after more than 20 bargaining sessions since March 2025. The bargaining unit includes registered nurses, occupational therapists, physical therapists, speech language pathologists, social workers and dieticians who voted to join the MNA in June 2024. They are demanding reasonable caseload limits, clear productivity standards, competitive wages and recruitment protections. MGB reported a $59.2 million operating gain in the year ending September 2025, with CEO Dr Anne Klibanski's compensation rising 40% to $8.4 million in 2024. The picket is scheduled for 15:30 to 17:00 and is not a strike.

CityBiz
Oct 7th, 2025
Affinia Therapeutics Secures $40M Series C

Avidity Partners has participated in a $40 million Series C funding round for Affinia Therapeutics, a company specializing in adeno-associated virus (AAV) gene therapies.

Business Wire
Oct 4th, 2025
Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubs...

PR Newswire
May 7th, 2025
Carta Healthcare Secures $18.25M Series B1 Funding

Carta Healthcare has secured $18 million in Series B1 funding to enhance its AI-powered clinical data abstraction and analytics. The investment, led by UPMC Enterprises with participation from several health ventures, will support Carta's growth in the life sciences market. The funding follows Carta's acquisition of Realyze Intelligence and aims to expand its customer base and improve healthcare data management. CEO Brent Dover highlighted the investment's role in scaling operations and product deployment.

Fierce Biotech
Feb 12th, 2025
Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody

Sanofi-backed Abcuro has secured